BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK. Pemetrexed in head and neck cancer: A systematic review. Oral Oncology 2013;49:492-501. [DOI: 10.1016/j.oraloncology.2013.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tuomainen K, Hyytiäinen A, Al-Samadi A, Ianevski P, Ianevski A, Potdar S, Turunen L, Saarela J, Kuznetsov S, Wahbi W, Risteli M, Mäkitie A, Monni O, Salo T. High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Sci Rep 2021;11:14755. [PMID: 34285300 DOI: 10.1038/s41598-021-94259-5] [Reference Citation Analysis]
2 Tong Y, Huang H, Pan H. Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells. Biochem Biophys Res Commun 2015;456:86-91. [PMID: 25446102 DOI: 10.1016/j.bbrc.2014.11.038] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
3 Korimerla N, Wahl DR. Interactions between Radiation and One-Carbon Metabolism. Int J Mol Sci 2022;23:1919. [PMID: 35163841 DOI: 10.3390/ijms23031919] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Ann Oncol 2016;27:1594-600. [PMID: 27177865 DOI: 10.1093/annonc/mdw204] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
5 Ferrari S, Severi L, Pozzi C, Quotadamo A, Ponterini G, Losi L, Marverti G, Costi MP. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth. Vitam Horm 2018;107:473-513. [PMID: 29544641 DOI: 10.1016/bs.vh.2017.12.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Kim JH, Kim SH, Jeon MK, Kim JE, Kim KH, Yun KH, Jeung HC, Rha SY, Ahn JH, Kim HS. Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial. ESMO Open 2021;6:100249. [PMID: 34482181 DOI: 10.1016/j.esmoop.2021.100249] [Reference Citation Analysis]
7 Liao KS, Wei CL, Chen JC, Zheng HY, Chen WC, Wu CH, Wang TJ, Peng YS, Chang PY, Lin YW. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells. Regul Toxicol Pharmacol 2016;81:353-61. [PMID: 27693704 DOI: 10.1016/j.yrtph.2016.09.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
8 Taddia L, D'Arca D, Ferrari S, Marraccini C, Severi L, Ponterini G, Assaraf YG, Marverti G, Costi MP. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resist Updat. 2015;23:20-54. [PMID: 26690339 DOI: 10.1016/j.drup.2015.10.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
9 Yu WX, Tang LN, Lin F, Yao Y, Shen Z. Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute. Oncol Lett 2014;8:2243-8. [PMID: 25289103 DOI: 10.3892/ol.2014.2472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Med 2015;4:1003-15. [PMID: 25828633 DOI: 10.1002/cam4.441] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
11 Sun Y, Wang Y, Han S, Xing B, Li H, Zhu Y, Zhou S, Wang X, Xu J, Tao R. Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther 2017;10:2595-600. [PMID: 28553124 DOI: 10.2147/OTT.S134684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]